Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Closed 11-22 16:00:00 EST

56.13

+0.91

+1.65%

High56.40	Low55.22	Vol599.50M
Open55.22	D1 Closing55.21	Amplitude2.14%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O11.86B	T/O Rate--	Tradable Shares0.00
P/B5.431127	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":56.12508,"timestamp":1732309199999,"preClose":55.2147,"halted":0,"volume":599499107,"delay":0,"changeRate":0.016488,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":0.910381,"latestTime":"11-22 16:00:00 EST","open":55.215595,"high":56.396885,"low":55.215595,"amount":11859856843.17512,"amplitude":0.021394,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.431127,"peRate":-50.989175,"turnoverRate":0.018957,"increases":391,"decrements":179,"flats":11,"marketCap":1473296845550.6562,"floatMarketCap":1321813422487.9062},"requestUrl":"/m/hq/s/BK4139/tweets","defaultTab":"tweets","newsList":[{"id":"2485442532","title":"Apollomics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2485442532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485442532?lang=en_us&edition=fundamental","pubTime":"2024-11-23 08:50","pubTimestamp":1732323004,"startTime":"0","endTime":"0","summary":"19:50 EST Apollomics (APLM) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apollomics-inc-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apollomics-inc-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APLM"],"gpt_icon":0},{"id":"2485241868","title":"US FDA approves BridgeBio's drug for rare heart condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2485241868","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485241868?lang=en_us&edition=fundamental","pubTime":"2024-11-23 08:21","pubTimestamp":1732321267,"startTime":"0","endTime":"0","summary":"Nov 22  - The U.S. Food and Drug Administration has approved BridgeBio's    drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's    blockbuster Vyndaqel.   The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy , in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","BK4581","LU1066053197.SGD","SG9999001176.USD","BK4588","LU1023059063.AUD","BK4599","LU0306806265.USD","LU0321505439.SGD","LU0058720904.USD","BK4007","IE00B19Z3581.USD","BK4533","LU0306807586.USD","LU1057294990.SGD","BK4568","SG9999002232.USD","SG9999001176.SGD","ALNY","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0321505868.SGD","LU1894683264.USD","PFE","SG9999011175.SGD","LU1066051498.USD","SG9999003800.SGD","BK4505","BBIO","LU1894683348.USD","LU0122379950.USD","LU0225771236.USD","BK4534","LU0985481810.HKD","SG9999013999.USD","LU0868494617.USD","BK4548","BK4592","BK4139","LU0234572021.USD","BK4585","BK4550","LU0225284248.USD","IE00BLSP4239.USD","LU0170899867.USD","SG9999002224.SGD","IE000M9KFDE8.USD","IE0002270589.USD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2485249752","title":"BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2485249752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485249752?lang=en_us&edition=fundamental","pubTime":"2024-11-23 08:18","pubTimestamp":1732321105,"startTime":"0","endTime":"0","summary":"BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm PatientsNov 22 (Reuters) - BridgeBio Pharma Inc BBIO.O:ATTRUBY (ACORAMIDIS), A NEAR ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241123:nTUABMSNLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","BK4139","BBIO","BK4585"],"gpt_icon":0},{"id":"2485824919","title":"Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2485824919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485824919?lang=en_us&edition=fundamental","pubTime":"2024-11-23 08:11","pubTimestamp":1732320690,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241123:nTUABMSNLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBIO","BK4139","BK4585","BK4588","BK4505"],"gpt_icon":0},{"id":"2485249195","title":"BridgeBio Pharma Inc - FDA Approves Attruby for Treatment of Attr-Cm","url":"https://stock-news.laohu8.com/highlight/detail?id=2485249195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485249195?lang=en_us&edition=fundamental","pubTime":"2024-11-23 08:11","pubTimestamp":1732320690,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241123:nTUABMSNLK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4588","BK4139","BBIO","BK4585"],"gpt_icon":0},{"id":"2485249193","title":"BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2485249193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485249193?lang=en_us&edition=fundamental","pubTime":"2024-11-23 08:11","pubTimestamp":1732320690,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241123:nTUABMSNLK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4588","BBIO","BK4139","BK4585"],"gpt_icon":0},{"id":"2485249160","title":"BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2485249160","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485249160?lang=en_us&edition=fundamental","pubTime":"2024-11-23 08:11","pubTimestamp":1732320690,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241123:nTUABMSNLK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","BBIO","BK4505","BK4585"],"gpt_icon":0},{"id":"2485241884","title":"GeneTether Therapeutics Reveals Q3 Results and New Drug Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2485241884","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485241884?lang=en_us&edition=fundamental","pubTime":"2024-11-23 08:05","pubTimestamp":1732320359,"startTime":"0","endTime":"0","summary":"GeneTether Therapeutics, Inc. (TSE:GTTX) has released an update. GeneTether Therapeutics Inc. has announced its third-quarter financial results and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genetether-therapeutics-reveals-q3-results-and-new-drug-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genetether-therapeutics-reveals-q3-results-and-new-drug-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ"],"gpt_icon":0},{"id":"2485124447","title":"A Letter to Myself Podcast: A mother’s battle to overcome drug addiction fuelled by the fear of losing her children","url":"https://stock-news.laohu8.com/highlight/detail?id=2485124447","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485124447?lang=en_us&edition=fundamental","pubTime":"2024-11-23 07:30","pubTimestamp":1732318200,"startTime":"0","endTime":"0","summary":"While serving time, Syamlia overheard someone saying they sold drugs to primary school kids. Shocked and worried, she thought about her three young children – and decided she needed to get clean. ","market":"us","thumbnail":"https://onecms-res.cloudinary.com/image/upload/s--yLmD61n5--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/10/23/a%20letter%20to%20mysself.jpg?itok=0Dm4Bws9","type":0,"news_type":0,"thumbnails":["https://onecms-res.cloudinary.com/image/upload/s--yLmD61n5--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/10/23/a%20letter%20to%20mysself.jpg?itok=0Dm4Bws9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/podcasts/mother-battle-drug-addiction-recovery-journey-fear-losing-children-syamlia-sri-dewi-letter-myself-4748671","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["SANA","BK4139"],"gpt_icon":0},{"id":"2485866248","title":"Press Release: NEXTRAN TRUCK CENTERS ACQUIRES QUINCY MACK, DECATUR MACK, AND H&L MACK","url":"https://stock-news.laohu8.com/highlight/detail?id=2485866248","media":"Dow Jones","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485866248?lang=en_us&edition=fundamental","pubTime":"2024-11-23 06:24","pubTimestamp":1732314240,"startTime":"0","endTime":"0","summary":"GAINESVILLE, Fla., Nov. 22, 2024 /PRNewswire/ -- Nextran Truck Centers, a full-service commercial truck dealer, announced today that it has acquired Quincy Mack, Decatur Mack, and H&L Mack, a well-respected Mack Trucks dealer with five locations across Illinois, Missouri, and Iowa. This strategic acquisition further expands Nextran's footprint from 26 to 31 locations across the United States.Established in 1993, Nextran Truck Centers is a full-service commercial truck dealership network located throughout Florida, Georgia, Alabama, Missouri, Colorado, Kansas, Wyoming, and now Illinois and Iowa. As the top-selling Mack Trucks dealer network in North America, Nextran's 31 locations are strategically positioned along key transportation routes throughout the United States. Nextran sells and services medium and heavy-duty trucks from top manufacturers such as Mack Trucks, Volvo Trucks, Isuzu, HINO, Kalmar Otta","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MACK","BK4139"],"gpt_icon":0},{"id":"2485210763","title":"BRIEF-Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2485210763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485210763?lang=en_us&edition=fundamental","pubTime":"2024-11-23 06:23","pubTimestamp":1732314197,"startTime":"0","endTime":"0","summary":"Nov 22 (Reuters) - Viracta Therapeutics Inc   :   * VIRACTA THERAPEUTICS INC - RECEIVES NOTICE OF NON-COMPLIANCE FROM NASDAQSource text: [ Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR",".IXIC","NDAQ","PSQ","BK4585","QLD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD","SQQQ","IE00B64PRP62.GBP","TQQQ","VIRX","LENZ","BK4588","NQmain","IE00BKPKM429.USD","QID","MNQmain","BK4139"],"gpt_icon":0},{"id":"2485210248","title":"Ocean Biomedical Faces Nasdaq Delisting Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2485210248","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485210248?lang=en_us&edition=fundamental","pubTime":"2024-11-23 06:20","pubTimestamp":1732314018,"startTime":"0","endTime":"0","summary":"The latest update is out from Ocean Biomedical ( ($OCEA) ). Ocean Biomedical, Inc. faces potential delisting from Nasdaq after failing to file its ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ocean-biomedical-faces-nasdaq-delisting-threat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ocean-biomedical-faces-nasdaq-delisting-threat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNQmain","BK4139","LU2210149790.SGD","OCEA","LU2095319765.USD","BK4585","SQQQ","QLD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","QID","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","TQQQ","PSQ","BK4588",".IXIC","NQmain"],"gpt_icon":0},{"id":"2485621746","title":"Mustang Bio files to sell 34.77M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2485621746","media":"seekingalpha","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485621746?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:56","pubTimestamp":1732312566,"startTime":"0","endTime":"0","summary":"Mustang Bio (NASDAQ:MBIO) filed a prospectus relates to the resale by the selling stockholders of 34,767,934 shares of common stock.\nThis preliminary prospectus is not an offer to sell.\nFiling","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4323554-mustang-bio-files-to-sell-3477m-shares-of-common-stock-for-holders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MBIO","BK4139"],"gpt_icon":0},{"id":"2485249187","title":"Top Research Reports for GE Aerospace, Fomento Economico & Waste Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2485249187","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485249187?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:56","pubTimestamp":1732312560,"startTime":"0","endTime":"0","summary":"GE Aerospace’s shares have underperformed the Zacks Transportation - Airlineindustry over the last six months . The Zacks analyst believes that the company has been dealing with high costs and expenses related to certain projects and restructuring activities, which are likely to affect its margins and profitability. Supply-chain disruptions in the defense market continue to take a toll on its operations. Also, foreign exchange headwinds are a cause for concern.However, global defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for the company. Also, it has been witnessing strength in its businesses, driven by robust demand for commercial engines, propulsion and additive technologies.Fomento Economico’s shares have underperformed the Zacks Beverages – Soft drinks industry over the past year . The Zacks analyst believes that the company’s Health division is dealing with complex, competitive, and regulatory i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jcQgRCy4_AMmUZU3FFZHWA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ea57bb703a94c7da7f678d3cc33be8c5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jcQgRCy4_AMmUZU3FFZHWA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ea57bb703a94c7da7f678d3cc33be8c5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-research-reports-ge-aerospace-215600902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2272731600.USD","DBX","FMX","LU1642822529.SGD","LU1720051017.SGD","IE00BD4GTT62.SGD","IE00B19Z3B42.SGD","CSTA.U","WM","LU2264538146.SGD","BK4559","LU2125909759.SGD","LU1894683264.USD","LU0072463663.USD","LU0820561909.HKD","MCHP","LU1585245621.USD","LU0170899867.USD","AEP","FMXUF","ECL","LU1548497426.USD","QSR","LU1992135472.HKD","LU0496367417.USD","INCY","CEG","LU1974910355.USD","LU2023250504.SGD","BK4141","USB","LU1551013425.SGD","LU1261432733.SGD","AEM","VIRT","LU2362541273.HKD","LU0323240290.USD","LU1093756168.USD","LU2362540622.SGD","LU2298064838.USD","BK4207","CAR","BK4139","BK4177","LU1815336760.USD","GB00BDT5M118.USD","LU2125910500.SGD","LU0689626769.HKD","LU1939255532.USD","AWRE","GE"],"gpt_icon":0},{"id":"2485674217","title":"BRIEF-Amarin Corp - Nasdaq Granted 180 Days To Regain Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2485674217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485674217?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:55","pubTimestamp":1732312517,"startTime":"0","endTime":"0","summary":"BRIEF-Amarin Corp - Nasdaq Granted 180 Days To Regain Nasdaq ComplianceNov 22 (Reuters) - Amarin Corporation PLC AMRN.O:AMARIN CORP - NASDAQ GRANTED 180 DAYS TO REGAIN NASDAQ COMPLIANCESource text: [https://tinyurl.com/bdhep7ek]Further company coverage: AMRN.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AMRN"],"gpt_icon":0},{"id":"2485217176","title":"Ocean Biomedical receives notice from Nasdaq regarding late filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2485217176","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485217176?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:53","pubTimestamp":1732312409,"startTime":"0","endTime":"0","summary":"Ocean Biomedical  has received a notice from The Nasdaq, stating that because the Co. has not yet filed its Quarterly Report on Form 10-Q, the Co. is not in compliance with Nasdaq Listing Rule. Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023.  The Co. is now delinquent in the filing of its form 10-Q for the period ended September 30, 2024. The Company intends to file the delinquent Forms 10-Q and 10-K as soon as practicable.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4323553-ocean-biomedical-receives-notice-from-nasdaq-regarding-late-filing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["OCEA","BK4139"],"gpt_icon":0},{"id":"2485217585","title":"Amarin Corp - Nasdaq Granted 180 Days to Regain Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2485217585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485217585?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:52","pubTimestamp":1732312346,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AMRN"],"gpt_icon":0},{"id":"2485521755","title":"Immunome Files Prospectus for Stock Offering By Selling Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2485521755","media":"MT Newswires Live","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485521755?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:52","pubTimestamp":1732312326,"startTime":"0","endTime":"0","summary":"Immunome (IMNM) filed a prospectus late Friday for the sale of 1.8 million shares by selling shareholders from time to time.The shares covered in the prospectus were issued under the stock issuance ag","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2485212740","title":"BRIEF-Ocean Biomedical Announces Receipt Of Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2485212740","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485212740?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:45","pubTimestamp":1732311947,"startTime":"0","endTime":"0","summary":"Nov 22 (Reuters) - Nasdaq Inc   :   * OCEAN BIOMEDICAL, INC. ANNOUNCES RECEIPT OF NOTICE FROM NASDAQ REGARDING LATE FILING OF QUARTERLY REPORT ON FORM 10-QSource text:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2357305700.SGD","IE00B3QW5Z07.USD","ON","BK4585","LU1720051017.SGD","IE00BD6J9T35.USD","BK4112","LU1854104046.USD","LU1861219969.SGD","MNQmain","BK4141","LU2360107325.USD","LU1861215975.USD","LU2210149790.SGD","LU0124384867.USD",".IXIC","BK4512","LU1548497426.USD","IE00B64PRP62.GBP","NDAQ","QLD","LU2095319765.USD","LU1720051108.HKD","LU2298322129.HKD","LU1854103824.USD","PSQ","BK4139","LU0348723411.USD","LU1978683503.SGD","LU1861214812.USD","QID","NQmain","OCEA","LU2210150020.SGD","LU1861220033.SGD","IE00BGHQF748.EUR","LU0724618433.USD","BK4588","SQQQ","TQQQ","IE00BZ199S13.USD"],"gpt_icon":0},{"id":"2485212712","title":"Ocean Biomedical, Inc. Announces Receipt of Notice From Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2485212712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485212712?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:45","pubTimestamp":1732311900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUA6JVYBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2095319765.USD","BK4585","IE00BGHQF748.EUR","OCEA","BK4588","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","BK4139","BK4112"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}